PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Prime Medicine Inc. Common Stock (PRME)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US74168J1016

Sector

Healthcare

IPO Date

Oct 20, 2022

Highlights

Market Cap

$393.48M

EPS (TTM)

-$2.06

Total Revenue (TTM)

$64.27M

Gross Profit (TTM)

$61.70M

EBITDA (TTM)

-$207.13M

Year Range

$2.81 - $9.80

Target Price

$13.09

Short %

23.09%

Short Ratio

13.89

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
PRME vs. BEAM PRME vs. NTLA PRME vs. SPY PRME vs. QQQ PRME vs. CRSP PRME vs. VGT
Popular comparisons:
PRME vs. BEAM PRME vs. NTLA PRME vs. SPY PRME vs. QQQ PRME vs. CRSP PRME vs. VGT

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Prime Medicine Inc. Common Stock, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%JulyAugustSeptemberOctoberNovemberDecember
-57.06%
7.29%
PRME (Prime Medicine Inc. Common Stock)
Benchmark (^GSPC)

Returns By Period

Prime Medicine Inc. Common Stock had a return of -70.20% year-to-date (YTD) and -72.24% in the last 12 months.


PRME

YTD

-70.20%

1M

-16.98%

6M

-57.96%

1Y

-72.24%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

23.11%

1M

-0.36%

6M

7.02%

1Y

23.15%

5Y*

12.80%

10Y*

11.01%

Monthly Returns

The table below presents the monthly returns of PRME, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-28.33%35.91%-18.89%-29.71%31.71%-20.68%9.14%-23.71%-9.58%0.26%-15.21%-70.20%
2023-5.38%-6.54%-25.14%11.95%-0.36%6.78%2.87%-12.14%-27.95%-31.97%11.86%22.04%-52.31%
202222.45%-8.66%8.09%20.88%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of PRME is 7, meaning it’s performing worse than 93% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of PRME is 77
Overall Rank
The Sharpe Ratio Rank of PRME is 99
Sharpe Ratio Rank
The Sortino Ratio Rank of PRME is 77
Sortino Ratio Rank
The Omega Ratio Rank of PRME is 1010
Omega Ratio Rank
The Calmar Ratio Rank of PRME is 55
Calmar Ratio Rank
The Martin Ratio Rank of PRME is 66
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Prime Medicine Inc. Common Stock (PRME) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for PRME, currently valued at -0.83, compared to the broader market-4.00-2.000.002.00-0.831.90
The chart of Sortino ratio for PRME, currently valued at -1.40, compared to the broader market-4.00-2.000.002.004.00-1.402.54
The chart of Omega ratio for PRME, currently valued at 0.85, compared to the broader market0.501.001.502.000.851.35
The chart of Calmar ratio for PRME, currently valued at -0.80, compared to the broader market0.002.004.006.00-0.802.81
The chart of Martin ratio for PRME, currently valued at -1.56, compared to the broader market0.0010.0020.00-1.5612.39
PRME
^GSPC

The current Prime Medicine Inc. Common Stock Sharpe ratio is -0.83. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Prime Medicine Inc. Common Stock with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
-0.83
1.90
PRME (Prime Medicine Inc. Common Stock)
Benchmark (^GSPC)

Dividends

Dividend History


Prime Medicine Inc. Common Stock doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-87.50%
-3.58%
PRME (Prime Medicine Inc. Common Stock)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Prime Medicine Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Prime Medicine Inc. Common Stock was 87.50%, occurring on Dec 18, 2024. The portfolio has not yet recovered.

The current Prime Medicine Inc. Common Stock drawdown is 87.50%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-87.5%Nov 2, 2022535Dec 18, 2024
-3.55%Oct 24, 20221Oct 24, 20221Oct 25, 20222

Volatility

Volatility Chart

The current Prime Medicine Inc. Common Stock volatility is 23.50%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%JulyAugustSeptemberOctoberNovemberDecember
23.50%
3.64%
PRME (Prime Medicine Inc. Common Stock)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Prime Medicine Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Prime Medicine Inc. Common Stock.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab